Recent clinical studies have suggested that phenylacetylglutamine (PAGln), a novel gut microbial metabolite, can mechanistically modulate patients' risk of developing cardiovascular disease (CVD) and ...
Through an international collaboration, scientists at St. Jude Children's Research Hospital leveraged data science, pharmacology and structural information to conduct an atomic-level investigation ...
This research enhances our understanding of βAR signaling and its implications for heart health. It highlights the potential of targeting βAR pathways for developing novel therapies for heart diseases ...
Efficacy and safety of disitamab vedotin in combination with RC148 versus albumin-bound paclitaxel ± toripalimab for patients with HR-negative HER2-low-expressing unresectable locally advanced or ...
An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR) agonist that mimics the effects of ...
Scientists have shown the efficacy of a new non-opioid oral painkiller known as ADRIANA, the world's first selective α2B-adrenoceptor antagonist – a receptor subtype not previously targeted for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results